Lasa Supergenerics Reports December 2024 Results Highlighting Sales Growth Amid Profit Challenges
Lasa Supergenerics has reported its financial results for the quarter ending December 2024, showing net sales of Rs 33.08 crore, a year-on-year growth of 24.08%. The earnings per share reached Rs 1.10, the highest in five quarters, while profit after tax declined to Rs -2.17 crore, indicating ongoing challenges.
Lasa Supergenerics, a microcap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending December 2024. The results indicate a notable shift in the company's evaluation, with its score rising to 4 from 2 over the past three months.The financial data reveals that Lasa Supergenerics achieved net sales of Rs 33.08 crore, reflecting a year-on-year growth of 24.08%. This positive sales trend suggests a robust demand for the company's products. Additionally, the earnings per share (EPS) reached Rs 1.10, marking the highest level in the last five quarters, which indicates an increase in profitability and enhanced earnings for shareholders.
Conversely, the profit after tax (PAT) reported a decline, standing at Rs -2.17 crore, which represents a significant year-on-year decrease of 48.9%. This aspect of the financial results points to challenges that the company is currently facing.
Overall, Lasa Supergenerics' recent financial performance showcases a mix of positive sales growth and profitability improvements, alongside notable challenges in profit margins.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
